K. M. Hirschi, Kary Ya Fang Tsai, M. Edwards, P. Hall, J. Mejia, Camilo Mejia, P. Reynolds, J. Arroyo
{"title":"The mTOR Family of Proteins and the Regulation of Trophoblast Invasion by Gas6","authors":"K. M. Hirschi, Kary Ya Fang Tsai, M. Edwards, P. Hall, J. Mejia, Camilo Mejia, P. Reynolds, J. Arroyo","doi":"10.35248/2576-1471.19.4.203","DOIUrl":"https://doi.org/10.35248/2576-1471.19.4.203","url":null,"abstract":"Objective: Preeclampsia is an obstetric complication wherein trophoblast invasion is decreased and high levels of serum Gas6 protein are present. Our objective was to assess members of the mTOR family that are plausibly involved in the invasion of trophoblast cells resulting from Gas6/AXL activation. Methods: Human first trimester cell line; (SW71), placental choriocarcinoma cell line (Jeg-3) and pulmonary alveolar type II-like cell line (A549) were treated with Gas6 or Gas6 and R428 (AXL receptor inhibitor) for 24 hours and real time cellular invasion was determined. Western blots were utilized to assess AXL receptor expression in treated and control cells. An Akt/mTOR phospho protein multiplex approach was used to determine the activity of mTOR related proteins. Results: As compared to controls, cell treatments showed: 1) decreased SW71 invasion and increased Jeg-3 and A549 invasion with Gas6, 2) reversal of invasive properties when Gas6 and R428 were co-administered in A549 and SW71 cells, 3) increased expression of pAXL cells with Gas6, 4) decreased pAXL expression when Gas6 and R428 were added, 5) a trend of decreased phosphorylation of mTOR related proteins by Gas6 in trophoblasts, and 6) a trend of increased phosphorylation of mTOR related proteins by Gas6 in lung cancer cells. Conclusions: These experiments revealed that mTOR family members are involved in the activation of AXL receptors during the regulation of cell invasion. The results provide important insight into the mechanism of AXL regulation of trophoblast cell invasion and identify potential avenues that may help in the understanding of obstetric complications associated with the aberrant invasion of trophoblast cells.","PeriodicalId":15288,"journal":{"name":"Journal of Cell Signaling","volume":"51 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88277385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"CD40 Agonist-activated mTORC1 Signaling Synergizes with PD-1 Checkpoint Blockade to Counter T-cell Exhaustion in Chronic Infection","authors":"Anjuman Ara, J. Xiang","doi":"10.35248/2576-1471.19.4.202","DOIUrl":"https://doi.org/10.35248/2576-1471.19.4.202","url":null,"abstract":"In chronic infection, T-cell exhaustion due to sustained programmed cell death (PD)-1 expression on cytotoxic T lymphocytes (CTLs) is one of the major issues leading to ineffective virus elimination. Programmed cell death ligand-1 (PD-L1) pathway blockade has been found to restore the function of exhausted CTLs during chronic infection. Understanding mechanisms involved in the conversion of CTL exhaustion is essential to improve disease therapy and vaccine protocols. In this commentary, we focus on the mechanism by which triggering CD40 signal alone can convert CTL exhaustion and synergize with PD-1 checkpoint blockade in rescuing exhausted CTLs.","PeriodicalId":15288,"journal":{"name":"Journal of Cell Signaling","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90663170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Discussion on the Relationship between Skin Lipid Metabolism and Whole-Body Glucose and Lipid Metabolism: Systematic Review.","authors":"Sabrina N Dumas, James M Ntambi","doi":"10.4172/2576-1471.1000189","DOIUrl":"https://doi.org/10.4172/2576-1471.1000189","url":null,"abstract":"<p><p>The obesity epidemic is a costly public health crisis that is not improving. In addition to the stigma and discomfort associated with carrying extra weight (at the expense of range of movement), obesity also goes hand-in-hand with co-morbidities like fatty liver disease, diabetes, cardiovascular disease, and increased risk of some forms of cancer. Currently there are no long-lasting treatments for obesity other than diet and exercise, which are not feasible for many populations that may not be equipped with the resources and/or support needed to lead a healthy lifestyle. Although there have been some pharmacological breakthroughs for treating obesity, each FDA-approved drug comes with unpleasant side-effects that make adherence unlikely. As a result, alternate approaches are necessary. In this review, we outline the relationship between skin lipid metabolism and whole-body glucose and lipid metabolism. Specifically, by summarizing studies that employed mice that were genetically modified to interrupt lipid metabolism in the skin. As a result, we propose that skin might be an overlooked, but viable target for combating obesity.</p>","PeriodicalId":15288,"journal":{"name":"Journal of Cell Signaling","volume":"3 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2576-1471.1000189","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36764627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"<i>Smyd1C</i> Mediates CD8 T Cell Death via Regulation of Bcl2-Mediated Restriction of outer Mitochondrial Membrane Integrity.","authors":"Hui Nie, Gary Rathbun, Haley Tucker","doi":"10.4172/2576-1471.1000163","DOIUrl":"https://doi.org/10.4172/2576-1471.1000163","url":null,"abstract":"<p><p>The SET and <i>Mynd</i> domain 1 (<i>Smyd1</i>) locus encodes three tissue-restricted isoforms. Two previously characterized isoforms, <i>Smyd1A</i> and <i>Smyd1B</i><b>,</b> are heart and skeletal muscle-restricted histone methyl transferases. Here we report that a third, non-catalytic isoform, <i>Smyd1C</i><b>,</b> is expressed predominantly in activated CD8 T cells. While <i>Smyd1C</i><b>-</b> deficient CD8 T cells undergo activation-induced apoptosis, neither of two classical mechanisms activation-induced cell death nor activated cell autonomous death are utilized. Instead, <i>Smyd1C</i> accumulates within both mitochondria and the immunological synapse where it associates with Bcl-2, FK506-Binding Protein 8/38 (FKBP38) and Calcineurin. This complex maintains Bcl-2 phosphorylation, enhanced mitochondrial localization, and restricted apoptosis of activated CD8 T cells. We suggest that CD8 T cell death is governed, in part, by <i>Smyd1C</i> regulation of Bcl2-mediated restriction of outer mitochondrial membrane integrity.</p>","PeriodicalId":15288,"journal":{"name":"Journal of Cell Signaling","volume":"2 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5699232/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35640554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Angiotensin-(1-7) and the Regulation of Anti-Fibrotic Signaling Pathways.","authors":"Mark C Chappell, Ebaa M Al Zayadneh","doi":"10.4172/2576-1471.1000134","DOIUrl":"https://doi.org/10.4172/2576-1471.1000134","url":null,"abstract":"Mark C. Chappell1* and Ebaa M. Al Zayadneh2 1Department of Surgery/Hypertension and Vascular Research, Cardiovascular Sciences Center, Wake Forest School of Medicine Winston-Salem, NC, USA 2Department of Physiology and Biochemistry, University of Jordan, Amman, Jordon *Corresponding author: Mark C. Chappell, Department of Surgery/Hypertension and Vascular Research, Cardiovascular Sciences Center, Wake Forest School of Medicine Winston-Salem, NC, USA, Tel: 336716-9236; E-mail: mchappel@wakehealth.edu","PeriodicalId":15288,"journal":{"name":"Journal of Cell Signaling","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2576-1471.1000134","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35154918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Role of MEK1 in TLR4 Mediated Signaling.","authors":"Christian Bauerfeld, Lobelia Samavati","doi":"10.4172/2576-1471.1000135","DOIUrl":"https://doi.org/10.4172/2576-1471.1000135","url":null,"abstract":"Christian Bauerfeld1 and Lobelia Samavati2,3* 1Department of Pediatrics, Division of Critical Care, Wayne State University School of Medicine and Children’s Hospital of Michigan, Detroit, USA 2Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Wayne State University School of Medicine and Detroit Medical Center, Detroit, USA 3Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, USA *Corresponding author: Lobelia Samavati, Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Wayne State University School of Medicine, 3 Hudson, 3990 John R Street, Detroit, MI, USA, Tel: (313)-745-1718; E-mail: ay6003@wayne.edu","PeriodicalId":15288,"journal":{"name":"Journal of Cell Signaling","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2576-1471.1000135","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35265199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Katherine A Minson, Deborah DeRyckere, Douglas K Graham
{"title":"The Current State of FLT3 Inhibition in Acute Myeloid Leukemia - Pitfalls and Promises.","authors":"Katherine A Minson, Deborah DeRyckere, Douglas K Graham","doi":"10.4172/2576-1471.1000166","DOIUrl":"https://doi.org/10.4172/2576-1471.1000166","url":null,"abstract":"Katherine A Minson1,2, Deborah DeRyckere1 and Douglas K Graham1* 1Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta and Emory University, USA 2Department of Pediatrics, Atlanta, GA, USA *Corresponding author: Douglas K Graham, Aflac Cancer and Blood Disorders Center, Children’s Healthcare of Atlanta and Emory University, Department of Pediatrics, Atlanta, GA, USA, Tel: (404) 727-5002; Fax: (404) 727-4455; E-mail: Douglas.Graham@choa.org","PeriodicalId":15288,"journal":{"name":"Journal of Cell Signaling","volume":"2 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/2576-1471.1000166","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36135817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Possible Crosstalk of MOB2 With NDR1/2 Kinases in Cell Cycle and DNA Damage Signaling.","authors":"Ramazan Gundogdu, Alexander Hergovich","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This article is the authors' opinion of the roles of the signal transducer Mps one binder 2 (MOB2) in the control of cell cycle progression and the DNA Damage Response (DDR). We recently found that endogenous MOB2 is required to prevent the accumulation of endogenous DNA damage in order to prevent the undesired, and possibly detrimental, activation of cell cycle checkpoints. In this regard, it is noteworthy that MOB2 has been linked biochemically to the regulation of the NDR1/2 (aka STK38/STK38L) protein kinases, which themselves have functions at different steps of the cell cycle. Therefore, we are speculating in this article about the possible connections of MOB2 with NDR1/2 kinases in cell cycle and DDR Signaling.</p>","PeriodicalId":15288,"journal":{"name":"Journal of Cell Signaling","volume":"1 ","pages":"125"},"PeriodicalIF":0.0,"publicationDate":"2016-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/31/1a/emss-71559.PMC5321467.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34766408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Possible Crosstalk of MOB2 With NDR1/2 Kinases in Cell Cycle and DNA Damage Signaling","authors":"R. Gundogdu, A. Hergovich","doi":"10.4172/2576-1471.1000125","DOIUrl":"https://doi.org/10.4172/2576-1471.1000125","url":null,"abstract":"This article is the authors’ opinion of the roles of the signal transducer Mps one binder 2 (MOB2) in the control of cell cycle progression and the DNA Damage Response (DDR). We recently found that endogenous MOB2 is required to prevent the accumulation of endogenous DNA damage in order to prevent the undesired, and possibly detrimental, activation of cell cycle checkpoints. In this regard, it is noteworthy that MOB2 has been linked biochemically to the regulation of the NDR1/2 (aka STK38/STK38L) protein kinases, which themselves have functions at different steps of the cell cycle. Therefore, we are speculating in this article about the possible connections of MOB2 with NDR1/2 kinases in cell cycle and DDR Signaling.","PeriodicalId":15288,"journal":{"name":"Journal of Cell Signaling","volume":"64 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73819600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Angiotensin Receptors: Structure, Function, Signaling and Clinical Applications.","authors":"Khuraijam Dhanachandra Singh, Sadashiva S Karnik","doi":"10.4172/jcs.1000111","DOIUrl":"https://doi.org/10.4172/jcs.1000111","url":null,"abstract":"<p><p>Angiotensinogen - a serpin family protein predominantly produced by the liver is systematically processed by proteases of the Renin Angiotensin system (RAS) generating hormone peptides. Specific cell surface receptors for at least three distinct angiotensin peptides produce distinct cellular signals that regulate system-wide physiological response to RAS. Two well characterized receptors are angiotensin type 1 receptor (AT1 receptor) and type 2 receptor (AT2 receptor). They respond to the octapeptide hormone angiotensin II. The oncogene product MAS is a putative receptor for Ang (1-7). While these are G-protein coupled receptors (GPCRs), the <i>in vivo</i> angiotensin IV binding sites may be type 2 transmembrane proteins. These four receptors together regulate cardiovascular, hemodynamic, neurological, renal, and endothelial functions; as well as cell proliferation, survival, matrix-cell interactions and inflammation. Angiotensin receptors are important therapeutic targets for several diseases. Thus, researchers and pharmaceutical companies are focusing on drugs targeting AT1 receptor than AT2 receptor, MAS and AngIV binding sites. AT1 receptor blockers are the cornerstone of current treatment for hypertension, heart failure, renal failure and many types of vascular diseases including atherosclerosis, aortic aneurism and Marfan syndrome.</p>","PeriodicalId":15288,"journal":{"name":"Journal of Cell Signaling","volume":"1 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4172/jcs.1000111","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34747364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}